<DOC>
	<DOCNO>NCT00419783</DOCNO>
	<brief_summary>The purpose study evaluate effect two dos bilastine ( 20 100 mg ) compare bilastine 20 mg administer ketoconazole 400 mg , moxifloxacin 400 mg , placebo . Subjects receive five study treatment crossover fashion administer daily 4 day .</brief_summary>
	<brief_title>A Randomized , Multiple Dose , Double Blind , 5-way Crossover Study Electrocardiographic ( ECG ) Effects Bilastine</brief_title>
	<detailed_description>This single center , Phase 1 study utilizes randomize , multiple-dose , double-blind , 5-way crossover design placebo control two active control . A minimum seven day washout period follow four day dose five treatment .</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy subject clinically significant finding note screen assessment include medical history , physical examination laboratory result Clinically significant medical condition Clinically significant history ECG abnormalities family history QTc interval syndrome Use tobacco and/or nicotine product &gt; 3 month prior screen Use prescription medication within 14 day prior screen Use counter medication ( include herbal product ) within 7 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Allergic rhinitis</keyword>
	<keyword>Urticaria</keyword>
</DOC>